8-K
Horizon Therapeutics Public Ltd Co 00-0000000 false 0001492426 0001492426 2020-05-06 2020-05-06

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 6, 2020

 

Horizon Therapeutics Public Limited Company

(Exact name of registrant as specified in its charter)

 

Ireland

 

001-35238

 

Not Applicable

(State or other jurisdiction

of incorporation)

 

(Commission

File No.)

 

(IRS Employer

Identification No.)

Connaught House, 1st Floor, 1 Burlington Road, Dublin 4, D04 C5Y6, Ireland

(Address of principal executive offices)

Registrant’s telephone number, including area code: 011-353-1-772-2100

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Ordinary shares, nominal

value $0.0001 per share

 

HZNP

 

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

 

 


Item 2.02 Results of Operations and Financial Condition. 

On May 6, 2020, Horizon Therapeutics plc issued a press release announcing its financial results for the first quarter ended March 31, 2020. A copy of this press release is attached hereto as Exhibit 99.1. 

The information in this Item 2.02 and the exhibit hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. 

Item 9.01 Financial Statements and Exhibits. 

(d) Exhibits. 

Exhibit 

   No.   

   

Description

         
 

99.1

   

Press Release of Horizon Therapeutics plc, dated May 6, 2020. 

         
 

104

   

Cover Page Interactive Data File (embedded within the Inline XBRL document).


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 6, 2020

 

 

HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY

             

 

 

By:

 

/s/ Paul W. Hoelscher

 

 

 

Paul W. Hoelscher

 

 

 

Executive Vice President and Chief Financial Officer

EX-99.1

Exhibit 99.1

 

LOGO

Horizon Therapeutics plc Reports Strong First-Quarter 2020 Financial Results;

Increasing TEPEZZA Full-Year 2020 Net Sales Guidance to Greater Than $200 Million

Due to Rapid Uptake; Increasing Full-Year 2020 Net Sales Guidance

— First-Quarter 2020 Net Sales of $355.9 Million Increased 27 Percent;

First-Quarter 2020 GAAP Net Loss of $13.6 Million; Adjusted EBITDA of $107.2 Million —

— Orphan Segment First-Quarter 2020 Net Sales of $245.4 Million, an Increase of 47 Percent;

KRYSTEXXA® First-Quarter 2020 Net Sales of $93.3 Million, an Increase of 78 Percent —

— TEPEZZA (teprotumumab-trbw) First-Quarter 2020 Net Sales of $23.5 Million Driven by

Strong Demand and Launch Execution, Significantly Exceeding Expectations;

Increasing Full-Year 2020 Guidance to Greater Than $200 Million from $30 Million to $40 Million —

— Increasing Full-Year 2020 Net Sales Guidance to $1.40 to $1.45 Billion Driven by Significantly Higher

TEPEZZA Net Sales and Reflecting Anticipated Impacts from COVID-19;

Revising Full-Year 2020 Adjusted EBITDA to $450 to $500 Million Guidance Reflecting Increased Investment in TEPEZZA

to Support Higher-Than-Expected Demand, New TEPEZZA Clinical Programs and HZN-825

— Acquired Curzion Pharmaceuticals, Inc. and Its Development-Stage Candidate

(Renamed HZN-825) for Diffuse Cutaneous Systemic Sclerosis, a Rare Rheumatic Disease —

— Announcing the Addition of Two New TEPEZZA Pipeline Programs —

— Donated More Than $1.5 Million to Support COVID-19 Response Efforts —

— Cash Position of $754.6 Million; Net Leverage of 1.3 Times as of March, 31, 2020 —

DUBLIN May 6, 2020 – Horizon Therapeutics plc (Nasdaq: HZNP) today announced its first-quarter 2020 financial results. The Company increased its full-year 2020 net sales guidance and revised its adjusted EBITDA guidance.

“We had a very strong start to 2020, highlighted by the early approval and rapid uptake of TEPEZZA, which significantly exceeded expectations, excellent KRYSTEXXA growth and our recent acquisition of HZN-825,” said Timothy Walbert, chairman, president and chief executive officer, Horizon. “We are increasing our full-year net sales guidance to account for significantly higher TEPEZZA net sales that more than offset the expected impact from COVID-19 this year, and we are widening both our net sales and adjusted EBITDA guidance ranges to account for future uncertainty. The fundamentals of our business are strong, including a robust cash position, and we continue to be very well positioned for the long term.”

Walbert continued, “Given the current environment, our priority is to safeguard the health, safety and welfare of patients and our employees, as well as to support our communities in their COVID-19 response efforts. I would like to recognize and applaud the tireless efforts of our employees who are helping patients access and maintain therapy, as well as all the healthcare professionals showing such incredible dedication and effort during this challenging time.”

 

Horizon Therapeutics plc      1  


LOGO

 

Financial Highlights

 

(in millions except for per share amounts and percentages)    Q1 20      Q1 19      %
Change
 

Net sales

   $ 355.9      $ 280.4        27  

Net loss

     (13.6      (32.9      (59

Non-GAAP net income

     83.2        53.9        54  

Adjusted EBITDA

     107.2        88.4        21  

Loss per share - diluted

     (0.07      (0.19      (62

Non-GAAP earnings per share - diluted

     0.40        0.30        33  

COVID-19

Horizon is closely monitoring the COVID-19 pandemic and its impact on the patients who are treated with the Company’s medicines, the communities in which the Company operates and its business. Horizon is making every effort as a company to help minimize the spread of COVID-19 and at the same time working to ensure continued patient access to Horizon’s medicines. The Company is maintaining its business operations remotely to protect the health and safety of Horizon employees who are ensuring business continuity and providing support to patients, physicians and partners virtually. The Company continues to closely monitor its supply chain and expects no impact at this time on the supply of its medicines. Horizon has provided more than $1.5 million in financial support for COVID-19 response efforts in Illinois, Dublin, South San Francisco, Washington D.C. and Canada. Many Horizon employees are also contributing their personal time and financial support to response efforts in line with Horizon’s mission to go to incredible lengths to improve people’s lives.

TEPEZZA Launch Progress

On Jan. 21, 2020, the Company received U.S. Food and Drug Administration (FDA) approval for TEPEZZA for the treatment of thyroid eye disease (TED). TEPEZZA, a fully human monoclonal antibody insulin-like growth factor-1 receptor (IGF-1R) inhibitor, is the first and only FDA-approved medicine for the treatment of TED. The Company initiated the commercial launch of TEPEZZA shortly after obtaining FDA approval. The first-quarter results for TEPEZZA greatly exceeded the Company’s expectations, generating net sales of $23.5 million.

Several factors contributed to the strong TEPEZZA first-quarter results and the Company’s increased full-year expectations:

 

   

Severity of Disease: TED is a rare, serious, progressive and vision-threatening autoimmune disease, and is associated with proptosis (eye bulging), diplopia (double vision), blurred vision, pain and facial disfigurement that can significantly impact patients’ quality of life. The severity of the disease is a motivating factor for patients seeking therapy.

 

Horizon Therapeutics plc      2  


LOGO

 

   

Pre-Launch Market Education Efforts: In early 2019, the Company initiated its pre-launch disease awareness, market development and market access efforts with the multi-functional field-based teams beginning to engage with key stakeholders in July of 2019. The pre-launch preparation included educating physicians, payors, sites of care and patients about the acute and debilitating nature of the disease and the urgency to treat. It also involved facilitating post-approval access to TEPEZZA by identifying an infusion site-of-care referral network and establishing a supportive patient services organization.

 

   

High Volume of Patient and Physician Interest Driven by Commercial Execution: The Company’s pre-launch efforts generated significant awareness and interest among physicians and TED patients, which resulted in a significantly higher number of patients beginning therapy than initially expected. Approximately 200 patients started TEPEZZA treatment in the first quarter.

“The tremendous success of the TEPEZZA launch reflects the potential of TEPEZZA and is a tribute to the strong execution and dedication of our TEPEZZA commercial team,” said Walbert. “Since the beginning of last year, the team has paved the way for launch, establishing a pathway for treatment and driving awareness of TED, the urgency to treat it and its highly debilitating symptoms – symptoms with which patients previously had to live, often for years. This has allowed many more patients to seek and start treatment, which epitomizes Horizon’s commitment to patients and the strength of our commercial strategy and execution.”

Walbert continued, “To maximize the future and long-term potential of TEPEZZA for TED patients, we announced today two new TEPEZZA development programs – one to evaluate TEPEZZA in the fibrotic phase of the disease and another to assess the potential for subcutaneous administration.”

First-Quarter and Recent Company Highlights

 

   

Announced New TEPEZZA Pooled Efficacy Data: In March 2020, new pooled efficacy data from the Phase 2 and 3 clinical trials of TEPEZZA were presented at a virtual ENDO 2020 news conference in lieu of the ENDO 2020, the Endocrine Society’s annual meeting, which was cancelled due to COVID-19. The analysis was conducted to determine if there were any differences in proptosis response to TEPEZZA based on patient demographic characteristics. The results showed that the medicine effectively reduces proptosis in TED patients, regardless of age, gender and smoking status, which are among several risk factors of the disease.

 

   

Expanded the Company’s Pipeline with Acquisition of Development-Stage Candidate HZN-825: On April 1, 2020, the Company completed the acquisition of Curzion Pharmaceuticals, Inc. and its lysophosphatidic acid 1 receptor (LPAR1) antagonist candidate (renamed HZN-825) for the treatment of diffuse cutaneous systemic sclerosis (dcSSc). A positive signal was observed in the 8-week placebo-controlled Phase 2a trial and data from the subsequent 24-week open-label extension period suggests that longer duration of treatment may demonstrate a meaningful benefit.

 

Horizon Therapeutics plc      3  


LOGO

 

   

Launched PROCYSBI® Delayed-Release Oral Granules in Packets: In April 2020, the Company launched PROCYSBI Delayed-Release Oral Granules in Packets after receiving FDA approval in February 2020. The new dosage form provides another administration option in addition to the PROCYSBI capsules for adults and children one year of age and older living with nephropathic cystinosis. The tear-open packets offer a convenient option for cystinosis patients who may have difficulty swallowing or have to administer medication through a gastrostomy tube (G-tube). Additionally, being able to access PROCYSBI granules in tear-open packets may help reduce the burden of managing multiple daily medications often faced by families living with cystinosis.

 

   

Acquired Certain Rights to Proceeds from Future Milestones and Royalties Related to TEPEZZA: In April 2020, in two separate transactions, the Company acquired the rights to proceeds from the future milestones and royalties related to TEPEZZA net sales from each of S.R. One and Lundbeckfond in exchange for an aggregate of $110 million. These transactions relate to the rights to approximately 71 percent of the $225 million in milestone payments due upon achievement of certain TEPEZZA annual worldwide net sales thresholds and approximately 71 percent of the 3 percent royalty tied to the portion of TEPEZZA annual worldwide net sales exceeding $300 million.

 

   

Best Workplace Award: In April 2020, Great Place to Work® and Fortune selected Horizon as one of the 2020 Best Workplaces in Health Care and Biopharma for the third consecutive year. The ranking is based on input from nearly 800,000 employees in the industry and evaluates multiple elements, including the extent to which employees trust leaders, the respect with which people are treated and the fairness of workplace decisions.

Research and Development Programs

 

   

HZN-825 dcSSc Program: HZN-825 is the Company’s LPAR1 antagonist in development for the treatment of dcSSc, a rare, chronic autoimmune disease marked by fibrosis, or skin thickening, in areas including hands, forearms, upper arms and thighs with no FDA-approved treatment options. The Company expects to begin a Phase 2b pivotal trial in the first half of 2021.

 

   

New TEPEZZA Trial in Fibrotic TED: The Company is planning to initiate a single-arm, open-label trial of TEPEZZA in patients with fibrotic TED (previously referred to as inactive TED). In fibrotic TED, the disease is no longer progressive or inflammatory; however, significant disease manifestations such as proptosis (eye bulging) and diplopia (double vision) remain.

 

   

New Potential TEPEZZA Subcutaneous Administration Program: The Company is planning to initiate a pharmacokinetic trial to explore subcutaneous dosing of TEPEZZA, which is currently administered by infusion. The objective of the trial is to inform the potential for additional administration options for TEPEZZA, which could provide greater flexibility for patients and physicians.

 

   

TEPEZZA dcSSc Exploratory Trial: As part of its evaluation of additional indications for TEPEZZA, the Company is planning to initiate an exploratory trial in dcSSc. The Company expects to initiate the trial by the end of 2020.

 

Horizon Therapeutics plc      4  


LOGO

 

   

KRYSTEXXA MIRROR Randomized Clinical Trial: The Company is currently evaluating the coadministration of KRYSTEXXA with methotrexate to increase the complete response rate of KRYSTEXXA in the MIRROR placebo-controlled randomized clinical trial (RCT), initiated in June 2019. The registrational trial is designed to enable the potential submission of results to the FDA to update the prescribing information. The MIRROR RCT follows the initial MIRROR open-label trial completed in 2019 that demonstrated a 79 percent complete response rate for patients using KRYSTEXXA with methotrexate. The 79 percent response rate is nearly double the 42 percent response rate in the KRYSTEXXA Phase 3 clinical program, which evaluated KRYSTEXXA alone. The combination was also well tolerated in the MIRROR open-label trial. Methotrexate is the immunomodulator most used by rheumatologists and has been shown to reduce anti-drug antibody formation to biologic therapies when used in conjunction with these therapies. The MIRROR RCT is approximately 80 percent enrolled and the Company expects to complete enrollment in the second half of 2020 with data available in 2021.

 

   

KRYSTEXXA PROTECT Trial in Kidney Transplant Patients with Uncontrolled Gout:

The Company is evaluating the effect of KRYSTEXXA on serum uric acid levels in kidney transplant patients with uncontrolled gout in its PROTECT open-label clinical trial, initiated in October 2019. Kidney transplant patients have more than a tenfold increase in the prevalence of gout when compared to the general population, and literature suggests that persistently high serum uric acid levels can be associated with organ rejection. Managing uncontrolled gout is one of the most common and significant unmet needs of kidney transplant patients.

 

   

KRYSTEXXA Shorter-Infusion Duration Trial: The Company is planning to initiate an open-label trial to evaluate the impact of administering KRYSTEXXA over a significantly shorter infusion duration. Currently, KRYSTEXXA is infused over a two-hour or longer timeframe. A shorter infusion duration could meaningfully improve the experience and convenience for patients, physicians and sites of care. The Company expects to initiate the trial by the end of 2020.

 

   

Next-Generation Programs for Uncontrolled Gout: The Company is pursuing early-stage development programs for next-generation biologics for uncontrolled gout to support and sustain the Company’s market leadership in this area. These include HZN-003 and HZN-007, as well as a collaboration with HemoShear Therapeutics, LLC, to discover new targets for gout.

First-Quarter Financial Results

Note: For additional detail and reconciliation of non-GAAP financial measures to the most directly comparable GAAP financial measures, please refer to the tables at the end of this release.

 

   

Net Sales: First-quarter 2020 net sales were $355.9 million, an increase of 27 percent.

 

   

Gross Profit: Under U.S. GAAP, the first-quarter 2020 gross profit ratio was 72.6 percent compared to 68.6 percent in the first quarter of 2019. The first-quarter 2020 non-GAAP gross profit ratio was 90.0 percent compared to 89.8 percent in the first quarter of 2019.

 

Horizon Therapeutics plc      5  


LOGO

 

   

Operating Expenses: First-quarter 2020 research and development (R&D) expenses were 7.6 percent of net sales and selling, general and administrative (SG&A) expenses were 69.6 percent of net sales. Non-GAAP R&D expenses were 5.8 percent of net sales, and non-GAAP SG&A expenses were 54.2 percent of net sales.

 

   

Income Tax Rate: The first-quarter 2020 income tax rate on a GAAP basis was 58.3 percent and the income tax expense rate on a non-GAAP basis was 12.8 percent.

 

   

Net Income (Loss): On a GAAP basis, first-quarter 2020 net loss was $13.6 million. First-quarter 2020 non-GAAP net income was $83.2 million.

 

   

Adjusted EBITDA: First-quarter 2020 adjusted EBITDA was $107.2 million.

 

   

Earnings (Loss) per Share: On a GAAP basis, diluted loss per share (EPS) in the first quarter of 2020 and 2019 were $0.07 and $0.19, respectively. Non-GAAP diluted earnings per share in the first quarter of 2020 and 2019 were $0.40 and $0.30, respectively. Weighted average shares outstanding used for calculating GAAP and non-GAAP diluted earnings per share in the first quarter of 2020 were 190.1 million and 213.1 million, respectively.

First-Quarter Segment Results

Management uses net sales and segment operating income to evaluate the performance of the Company’s two segments, the orphan segment and the inflammation segment. While segment operating income contains certain adjustments to the directly comparable GAAP figures in the Company’s consolidated financial results, it is considered to be prepared in accordance with GAAP for purposes of presenting the Company’s segment operating results. Prior to the first quarter of 2020, the two operating segments were the orphan and rheumatology segment, which included RAYOS®, and the inflammation segment. Beginning with the first quarter of 2020, RAYOS was moved to the inflammation segment and the orphan and rheumatology segment was renamed the orphan segment.

 

Horizon Therapeutics plc      6  


LOGO

 

Orphan Segment

 

(in millions except for percentages)    Q1 20      Q1 19      %
Change
 

KRYSTEXXA®

     93.3        52.3        78  

RAVICTI®

     61.2        49.9        23  

PROCYSBI®

     38.3        39.6        (3

ACTIMMUNE®

     26.5        21.7        22  

TEPEZZATM

     23.5        —          NM  

BUPHENYL®

     2.3        2.8        (16

QUINSAIRTM

     0.3        0.2        64  
  

 

 

    

 

 

    

Orphan Net Sales

   $ 245.4      $ 166.5        47  
  

 

 

    

 

 

    

Orphan Segment Operating Income

   $ 54.4      $ 36.7        48  

 

   

First-quarter 2020 net sales of the orphan segment, the Company’s strategic growth segment, were $245.4 million, an increase of 47 percent over the prior year’s quarter, driven by and strong continued growth of KRYSTEXXA and RAVICTI, as well as the launch of TEPEZZA.

 

   

First-quarter 2020 orphan segment operating income was $54.4 million, which includes significant investment spend associated with the commercial launch of TEPEZZA.

Inflammation Segment

 

(in millions except for percentages)    Q1 20      Q1 19      %
Change
 

PENNSAID 2%®

     41.6        50.2        (17

DUEXIS®

     31.3        29.5        6  

VIMOVO®(1)

     19.4        14.0        38  

RAYOS®

     18.2        19.4        (6

MIGERGOT®(2)

     —          0.8        NM  
  

 

 

    

 

 

    

Inflammation Net Sales

   $ 110.5      $ 113.9        (3
  

 

 

    

 

 

    

Inflammation Segment Operating Income

   $ 51.9      $ 51.4        1  

 

  (1)

On Feb. 27, 2020, Dr. Reddy’s Laboratory initiated an at-risk launch of generic VIMOVO in the United States.

  (2)

In June 2019, the Company divested the rights to MIGERGOT.

 

   

First-quarter 2020 net sales of the inflammation segment were $110.5 million and segment operating income was $51.9 million.

 

Horizon Therapeutics plc      7  


LOGO

 

Cash Flow Statement and Balance Sheet Highlights

 

   

On a GAAP basis in the first quarter of 2020, cash used in operating activities was $62.6 million. On a non-GAAP basis, cash used in operating activities was $62.4 million.

 

   

The Company had cash and cash equivalents of $754.6 million as of March 31, 2020.

 

   

As of March 31, 2020, the total principal amount of debt outstanding was $1.418 billion, consisting of $418 million in senior secured term loans due 2026, $600 million of senior notes due 2027 and $400 million of exchangeable senior notes due 2022. As of March 31, 2020, net debt was $663.4 million and the net-debt-to-last-12-months adjusted EBITDA leverage (net leverage) ratio was 1.3 times. The Company has no maintenance covenants on its debt.

Revised 2020 Guidance

The Company now expects full-year 2020 net sales to range between $1.40 billion and $1.45 billion, an increase from the previous range of $1.40 billion to $1.42 billion, reflecting the significant increase in full-year TEPEZZA net sales guidance, offset by the current estimated impact of COVID-19 on its medicines. The Company now expects TEPEZZA full-year net sales of greater than $200 million, compared to the previous guidance of $30 million to $40 million. Full-year 2020 adjusted EBITDA is now expected to range between $450 million and $500 million, revised from the previous guidance range of $485 million to $500 million and reflects increased investment in TEPEZZA to support higher-than-expected demand, new TEPEZZA clinical programs and HZN-825. The updated guidance assumes that healthcare activity begins to return in the second half of 2020.

Webcast

At 8 a.m. EST / 1 p.m. IST today, the Company will host a live webcast to review its financial and operating results and provide a general business update. The live webcast and a replay may be accessed at http://ir.horizontherapeutics.com. Please connect to the Company’s website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. A replay of the webcast will be available approximately two hours after the live webcast.

About Horizon

Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, please visit www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.

 

Horizon Therapeutics plc      8  


LOGO

 

Note Regarding Use of Non-GAAP Financial Measures

EBITDA, or earnings before interest, taxes, depreciation and amortization, and adjusted EBITDA are used and provided by Horizon as non-GAAP financial measures. Horizon provides certain other financial measures such as non-GAAP net income, non-GAAP diluted earnings per share, non-GAAP gross profit and gross profit ratio, non-GAAP operating expenses, non-GAAP operating income, non-GAAP tax rate, non-GAAP operating cash flow, net leverage ratio and net debt, each of which include adjustments to GAAP figures. These non-GAAP measures are intended to provide additional information on Horizon’s performance, operations, expenses, profitability and cash flows. Adjustments to Horizon’s GAAP figures as well as EBITDA exclude acquisition and/or divestiture-related expenses, charges related to the discontinuation of ACTIMMUNE development for Friedreich’s ataxia, gain or loss from sale of assets, upfront, progress and milestone payments related to license and collaboration agreements, litigation settlements, loss on debt extinguishment, costs of debt refinancing, drug manufacturing harmonization costs, restructuring and realignment costs, the income tax effect on pre-tax non-GAAP adjustments and other non-GAAP income tax adjustments, as well as non-cash items such as share-based compensation, depreciation and amortization, non-cash interest expense, long-lived asset impairment charges and other non-cash adjustments. Certain other special items or substantive events may also be included in the non-GAAP adjustments periodically when their magnitude is significant within the periods incurred. Horizon maintains an established non-GAAP cost policy that guides the determination of what costs will be excluded in non-GAAP measures. Horizon believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Horizon’s financial and operating performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of the Company’s historical and expected 2020 financial results and trends and to facilitate comparisons between periods and with respect to projected information. In addition, these non-GAAP financial measures are among the indicators Horizon’s management uses for planning and forecasting purposes and measuring the Company’s performance. For example, adjusted EBITDA is used by Horizon as one measure of management performance under certain incentive compensation arrangements. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies. Horizon has not provided a reconciliation of its full-year 2020 adjusted EBITDA outlook to an expected net income (loss) outlook because certain items such as acquisition/divestiture-related expenses and share-based compensation that are a component of net income (loss) cannot be reasonably projected due to the significant impact of changes in Horizon’s stock price, the variability associated with the size or timing of acquisitions/divestitures and other factors. These components of net income (loss) could significantly impact Horizon’s actual net income (loss).

Forward-Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to Horizon’s full-year 2020 net sales and adjusted EBITDA guidance; expected financial performance and operating results in future periods, including potential growth in net sales of certain of Horizon’s medicines; development plans; expected timing of clinical trials, studies and regulatory submissions; potential market opportunity for and benefits of Horizon’s medicines and medicine candidates; and business and other statements that are not historical facts. These forward-looking statements are based on Horizon’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks that Horizon’s actual future financial and operating results may differ from its expectations or goals; Horizon’s

 

Horizon Therapeutics plc      9  


LOGO

 

ability to grow net sales from existing medicines; impacts of the COVID-19 pandemic and actions taken to slow its spread, including impacts on sales of Horizon’s medicines and potential delays in clinical trials; the availability of coverage and adequate reimbursement and pricing from government and third-party payers; risks relating to Horizon’s ability to successfully implement its business strategies; risks inherent in developing novel medicine candidates and existing medicines for new indications; risks associated with regulatory approvals; risks in the ability to recruit, train and retain qualified personnel; competition, including potential generic competition; the ability to protect intellectual property and defend patents; regulatory obligations and oversight, including any changes in the legal and regulatory environment in which Horizon operates and those risks detailed from time-to-time under the caption “Risk Factors” and elsewhere in Horizon’s filings and reports with the SEC. Horizon undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information.

Contacts:

 

Investors:    U.S. Media:
Tina Ventura    Geoff Curtis
Senior Vice President,    Executive Vice President,
Investor Relations    Corporate Affairs & Chief Communications Officer
investor-relations@horizontherapeutics.com    media@horizontherapeutics.com
Ruth Venning    Ireland Media:
Executive Director,    Ray Gordon
Investor Relations    Gordon MRM
investor-relations@horizontherapeutics.com    ray@gordonmrm.ie

 

Horizon Therapeutics plc      10  


LOGO

 

Horizon Therapeutics plc

Condensed Consolidated Statements of Operations (Unaudited)

(in thousands, except share and per share data)

 

     Three Months Ended March 31,  
     2020     2019  

Net sales

   $ 355,909     $ 280,371  

Cost of goods sold

     97,416       88,142  
  

 

 

   

 

 

 

Gross profit

     258,493       192,229  
  

 

 

   

 

 

 

OPERATING EXPENSES:

    

Research and development

     27,209       21,725  

Selling, general and administrative

     247,775       172,299  
  

 

 

   

 

 

 

Total operating expenses

     274,984       194,024  
  

 

 

   

 

 

 

Operating loss

     (16,491     (1,795
  

 

 

   

 

 

 

OTHER EXPENSE, NET:

    

Interest expense, net

     (17,344     (27,530

Loss on debt extinguishment

     —         (5,586

Foreign exchange gain (loss)

     776       (61

Other income, net

     442       189  
  

 

 

   

 

 

 

Total other expense, net

     (16,126     (32,988
  

 

 

   

 

 

 

Loss before benefit for income taxes

     (32,617     (34,783

Benefit for income taxes

     (19,026     (1,920
  

 

 

   

 

 

 

Net loss

   $ (13,591   $ (32,863
  

 

 

   

 

 

 

Net loss per ordinary share - basic and diluted

   $ (0.07   $ (0.19
  

 

 

   

 

 

 

Weighted average ordinary shares outstanding - basic and diluted

     190,072,112       172,789,209  
  

 

 

   

 

 

 

 

Horizon Therapeutics plc      11  


LOGO

 

Horizon Therapeutics plc

Condensed Consolidated Balance Sheets (Unaudited)

(in thousands, except share data)

 

     As of  
     March 31,
2020
    December 31,
2019
 

ASSETS

    

CURRENT ASSETS:

    

Cash and cash equivalents

   $ 754,638     $ 1,076,287  

Restricted cash

     3,624       3,752  

Accounts receivable, net

     425,405       408,685  

Inventories, net

     68,170       53,802  

Prepaid expenses and other current assets

     161,903       143,577  
  

 

 

   

 

 

 

Total current assets

     1,413,740       1,686,103  
  

 

 

   

 

 

 

Property and equipment, net

     142,420       30,159  

Developed technology, net

     1,745,625       1,698,808  

Other intangible assets, net

     3,619       3,820  

Goodwill

     413,669       413,669  

Deferred tax assets, net

     552,722       555,165  

Other assets

     42,925       48,310  
  

 

 

   

 

 

 

Total assets

   $ 4,314,720     $ 4,436,034  
  

 

 

   

 

 

 

LIABILITIES AND SHAREHOLDERS’ EQUITY

    

CURRENT LIABILITIES:

    

Accounts payable

   $ 50,124     $ 21,514  

Accrued expenses

     205,988       235,234  

Accrued trade discounts and rebates

     336,320       466,421  
  

 

 

   

 

 

 

Total current liabilities

     592,432       723,169  
  

 

 

   

 

 

 

LONG-TERM LIABILITIES:

    

Exchangeable notes, net

     356,551       351,533  

Long-term debt, net

     1,001,809       1,001,308  

Deferred tax liabilities, net

     89,721       94,247  

Other long-term liabilities

     85,868       80,328  
  

 

 

   

 

 

 

Total long-term liabilities

     1,533,949       1,527,416  
  

 

 

   

 

 

 

COMMITMENTS AND CONTINGENCIES

    

SHAREHOLDERS’ EQUITY:

    

Ordinary shares, $0.0001 nominal value; 600,000,000 shares authorized at March 31, 2020 and December 31, 2019, 190,962,613 and 188,402,040 shares issued at March 31, 2020 and December 31, 2019, respectively, and 190,578,247 and 188,017,674 shares outstanding at March 31, 2020 and December 31, 2019, respectively

     19       19  

Treasury stock, 384,366 ordinary shares at March 31, 2020 and December 31, 2019

     (4,585     (4,585

Additional paid-in capital

     2,814,408       2,797,602  

Accumulated other comprehensive loss

     (2,230     (1,905

Accumulated deficit

     (619,273     (605,682
  

 

 

   

 

 

 

Total shareholders’ equity

     2,188,339       2,185,449  
  

 

 

   

 

 

 

Total liabilities and shareholders’ equity

   $ 4,314,720     $ 4,436,034  
  

 

 

   

 

 

 

 

Horizon Therapeutics plc      12  


LOGO

 

Horizon Therapeutics plc

Condensed Consolidated Statements of Cash Flows (Unaudited)

(in thousands)

 

     Three Months Ended March 31,  
     2020     2019  

CASH FLOWS FROM OPERATING ACTIVITIES:

    

Net loss

   $ (13,591   $ (32,863

Adjustments to reconcile net loss to net cash (used in) provided by operating activities:

    

Depreciation and amortization expense

     65,741       58,891  

Equity-settled share-based compensation

     56,421       27,548  

Loss on debt extinguishment

     —         5,586  

Amortization of debt discount and deferred financing costs

     5,569       5,851  

Deferred income taxes

     (2,082     1,502  

Foreign exchange and other adjustments

     (190     404  

Changes in operating assets and liabilities:

    

Accounts receivable

     (16,869     60,769  

Inventories

     (14,444     (847

Prepaid expenses and other current assets

     (24,953     111  

Accounts payable

     28,551       6,416  

Accrued trade discounts and rebates

     (129,940     (50,904

Accrued expenses

     (28,087     (21,336

Deferred revenues

     —         (67

Other non-current assets and liabilities

     11,281       (4,893
  

 

 

   

 

 

 

Net cash (used in) provided by operating activities

     (62,593     56,168  
  

 

 

   

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES:

    

Payments for acquisition

     (105,200     —    

Change in escrow deposit for property purchase

     6,000       —    

Purchases of property and equipment

     (119,004     (1,849
  

 

 

   

 

 

 

Net cash used in investing activities

     (218,204     (1,849
  

 

 

   

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES:

    

Net proceeds from the issuance of ordinary shares

     —         327,750  

Repayment of term loans

     —         (300,000

Proceeds from the issuance of ordinary shares in connection with stock option exercises

     7,050       10,042  

Payment of employee withholding taxes relating to share-based awards

     (46,664     (17,171
  

 

 

   

 

 

 

Net cash (used in) provided by financing activities

     (39,614     20,621  
  

 

 

   

 

 

 

Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash

     (1,366     (518
  

 

 

   

 

 

 

Net (decrease) increase in cash, cash equivalents and restricted cash

     (321,777     74,422  

Cash, cash equivalents and restricted cash, beginning of the period(1)

     1,080,039       962,117  
  

 

 

   

 

 

 

Cash, cash equivalents and restricted cash, end of the period(1)

   $ 758,262     $ 1,036,539  
  

 

 

   

 

 

 

 

(1)

Amounts include restricted cash balance in accordance with ASU No. 2016-18. Cash and cash equivalents excluding restricted cash are shown on the balance sheet.

 

Horizon Therapeutics plc      13  


LOGO

 

Horizon Therapeutics plc

GAAP to Non-GAAP Reconciliations

Net Income and Earnings Per Share (Unaudited)

(in thousands, except share and per share data)

 

     Three Months Ended March 31,  
     2020     2019  

GAAP net loss

   $ (13,591   $ (32,863

Non-GAAP adjustments:

    

Acquisition/divestiture-related costs

     (6     1,345  

Restructuring and realignment costs

     —         20  

Amortization and step-up:

    

Intangible amortization expense

     58,575       57,417  

Inventory step-up expense

     —         115  

Amortization of debt discount and deferred financing costs

     5,569       5,912  

Share-based compensation

     56,421       27,548  

Depreciation

     7,165       1,473  

Upfront, progress and milestone payments related to license and collaboration agreements

     —         2,000  

Fees related to refinancing activities

     54       142  

Loss on debt extinguishment

           5,586  

Drug substance harmonization costs

     290       80  

Charges relating to discontinuation of Friedreich’s ataxia program

     —         (79
  

 

 

   

 

 

 

Total of pre-tax non-GAAP adjustments

     128,068       101,559  

Income tax effect of pre-tax non-GAAP adjustments

     (31,262     (14,751
  

 

 

   

 

 

 

Total of non-GAAP adjustments

     96,806       86,808  
  

 

 

   

 

 

 

Non-GAAP Net Income

   $ 83,215     $ 53,945  
  

 

 

   

 

 

 

Non-GAAP Earnings Per Share:

    

Weighted average ordinary shares - Basic

     190,072,112       172,789,209  
  

 

 

   

 

 

 

Non-GAAP Earnings Per Share - Basic:

    

GAAP loss per share - Basic

   $ (0.07   $ (0.19

Non-GAAP adjustments

     0.51       0.50  
  

 

 

   

 

 

 

Non-GAAP earnings per share - Basic

   $ 0.44     $ 0.31  
  

 

 

   

 

 

 

Non-GAAP Net Income

     83,215       53,945  

Effect of assumed conversion of Exchangeable Senior Notes, net of tax

     1,875       —    
  

 

 

   

 

 

 

Numerator - non-GAAP Net Income

     85,090       53,945  
  

 

 

   

 

 

 

Weighted average ordinary shares - Diluted

    

Weighted average ordinary shares - Basic

     190,072,112       172,789,209  

Ordinary share equivalents

     22,984,847       7,496,024  
  

 

 

   

 

 

 

Denominator - weighted average ordinary shares – Diluted

     213,056,959       180,285,233  
  

 

 

   

 

 

 

Non-GAAP Earnings Per Share - Diluted

    

GAAP loss per share - Diluted

   $ (0.07   $ (0.19

Non-GAAP adjustments

     0.51       0.50  

Diluted earnings per share effect of ordinary share equivalents

     (0.04     (0.01
  

 

 

   

 

 

 

Non-GAAP earnings per share - Diluted

   $ 0.40     $ 0.30  
  

 

 

   

 

 

 

 

Horizon Therapeutics plc      14  


LOGO

 

Horizon Therapeutics plc

GAAP to Non-GAAP Reconciliations

EBITDA (Unaudited)

(in thousands)

 

     Three Months Ended March 31,  
     2020     2019  

GAAP net loss

   $ (13,591   $ (32,863

Depreciation

     7,165       1,473  

Amortization and step-up:

    

Intangible amortization expense

     58,575       57,417  

Inventory step-up expense

     —         115  

Interest expense, net (including amortization of debt discount and deferred financing costs)

     17,344       27,530  

Benefit for income taxes

     (19,026     (1,920
  

 

 

   

 

 

 

EBITDA

   $ 50,467     $ 51,752  
  

 

 

   

 

 

 

Other non-GAAP adjustments:

    

Acquisition/divestiture-related costs

     (6     1,345  

Restructuring and realignment costs

     —         20  

Share-based compensation

     56,421       27,548  

Upfront, progress and milestone payments related to license and collaboration agreements

     —         2,000  

Fees related to refinancing activities

     54       142  

Loss on debt extinguishment

     —         5,586  

Drug substance harmonization costs

     290       80  

Charges relating to discontinuation of Friedreich’s ataxia program

     —         (79
  

 

 

   

 

 

 

Total of other non-GAAP adjustments

     56,759       36,642  
  

 

 

   

 

 

 

Adjusted EBITDA

   $ 107,226     $ 88,394  
  

 

 

   

 

 

 

 

Horizon Therapeutics plc      15  


LOGO

 

Horizon Therapeutics plc

GAAP to Non-GAAP Reconciliations

Operating Income (Unaudited)

(in thousands)

 

     Three Months Ended March 31,  
     2020     2019  

GAAP operating loss

   $ (16,491   $ (1,795

Non-GAAP adjustments:

    

Acquisition/divestiture-related costs

     284       1,202  

Restructuring and realignment costs

     —         20  

Amortization and step-up:

    

Intangible amortization expense

     58,575       57,417  

Inventory step-up expense

     —         115  

Share-based compensation

     56,421       27,548  

Depreciation

     7,165       1,473  

Upfront, progress and milestone payments related to license and collaboration agreements

     —         2,000  

Fees related to refinancing activities

     54       142  

Drug substance harmonization costs

     290       80  

Charges relating to discontinuation of Friedreich’s ataxia program

     —         (79
  

 

 

   

 

 

 

Total of non-GAAP adjustments

     122,789       89,918  
  

 

 

   

 

 

 

Non-GAAP operating income

   $ 106,298     $ 88,123  
  

 

 

   

 

 

 

Orphan segment operating income

     54,356       36,704  

Inflammation segment operating income

     51,942       51,419  
  

 

 

   

 

 

 

Total segment operating income

   $ 106,298     $ 88,123  

Foreign exchange gain/(loss)

     776       (61

Other income, net

     152       332  
  

 

 

   

 

 

 

Adjusted EBITDA

   $ 107,226     $ 88,394  
  

 

 

   

 

 

 

 

Horizon Therapeutics plc      16  


LOGO

 

Horizon Therapeutics plc

GAAP to Non-GAAP Reconciliations

Gross Profit and Operating Cash Flow (Unaudited)

(in thousands, except percentages)

 

     Three Months Ended March 31,  
     2020     2019  

Non-GAAP Gross Profit:

    

GAAP gross profit

   $ 258,493     $ 192,229  

Non-GAAP gross profit adjustments:

    

Acquisition/divestiture-related costs

     —         1,114  

Intangible amortization expense

     58,374       57,218  

Inventory step-up expense

     —         115  

Share-based compensation

     2,689       1,040  

Depreciation

     328       159  

Drug substance harmonization costs

     290       80  

Charges relating to discontinuation of Friedreich’s ataxia program

     —         (79
  

 

 

   

 

 

 

Total of Non-GAAP adjustments

     61,681       59,647  
  

 

 

   

 

 

 

Non-GAAP gross profit

   $ 320,174     $ 251,876  
  

 

 

   

 

 

 

GAAP gross profit %

     72.6     68.6

Non-GAAP gross profit %

     90.0     89.8

GAAP cash (used in) provided by operating activities

   $ (62,593   $ 56,168  

Cash payments for acquisition/divestiture-related costs

     (17     353  

Cash payments for restructuring and realignment costs

     95       2,043  

Cash payments for upfront, progress and milestone payments related to license and collaboration agreement

     —         2,000  

Cash payments drug substance harmonization costs

     —         647  

Cash payments for discontinuation of Friedreich’s ataxia program

     —         930  

Cash payments relating to refinancing activities

     73       9  
  

 

 

   

 

 

 

Non-GAAP operating cash flow

   $ (62,442   $ 62,150  
  

 

 

   

 

 

 

 

Horizon Therapeutics plc      17  


LOGO

 

Horizon Therapeutics plc

GAAP to Non-GAAP Reconciliations

EBITDA (Unaudited)

(in thousands)

 

     Twelve Months
Ended December 31,
 
     2019  

GAAP net income

   $ 573,020  

Depreciation

     6,733  

Amortization and step-up:

  

Intangible amortization expense

     230,424  

Inventory step-up expense

     89  

Interest expense, net (including amortization of debt discount and deferred financing costs)

     87,089  

Benefit for income taxes

     (593,244
  

 

 

 

EBITDA

   $ 304,111  
  

 

 

 

Other non-GAAP adjustments:

  

Acquisition/divestiture-related costs

     3,556  

Restructuring and realignment costs

     237  

Share-based compensation

     91,215  

Litigation settlements

     1,000  

Upfront, progress and milestone payments related to

  

license and collaboration agreements

     9,073  

Fees related to refinancing activities

     2,292  

Loss on debt extinguishment

     58,835  

Drug substance harmonization costs

     457  

Charges relating to discontinuation of Friedreich’s ataxia program

     1,076  

Gain on sale of assets

     10,963  
  

 

 

 

Total of other non-GAAP adjustments

     178,704  
  

 

 

 

Adjusted EBITDA

   $ 482,815  
  

 

 

 

 

Horizon Therapeutics plc      18  


LOGO

 

Horizon Therapeutics plc

Net Debt Reconciliation (Unaudited)

(in thousands)

 

     As of  
     March 31,
2020
     December 31,
2019
 

Long-term debt, net of current

   $ 1,001,809      $ 1,001,308  

Exchangeable notes, net

     356,551        351,533  
  

 

 

    

 

 

 

Total Debt

     1,358,360        1,352,841  

Debt discount

     54,567        59,922  

Deferred financing fees

     5,099        5,263  
  

 

 

    

 

 

 

Total Principal Amount of Debt

     1,418,026        1,418,026  

Less: cash and cash equivalents

     754,638        1,076,287  
  

 

 

    

 

 

 

Net Debt

   $ 663,388      $ 341,739  
  

 

 

    

 

 

 

 

Horizon Therapeutics plc      19  


LOGO

 

Horizon Therapeutics plc

GAAP to Non-GAAP Tax Rate Reconciliation (Unaudited)

(in millions, except percentages and per share amounts)

 

     Q1 2020  
     Pre-tax Net
(Loss) Income
    Income Tax
(Benefit) Expense
    Tax Rate     Net Income
(Loss)
    Diluted Earnings
(Loss) Per Share
 

As reported - GAAP

   $ (32.6   $ (19.0     58.3   $ (13.6   $ (0.07

Non-GAAP adjustments

     128.1       31.3         96.8    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP

   $ 95.5     $ 12.2       12.8   $ 83.2     $ 0.40  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 
     Q1 2019  
     Pre-tax Net
(Loss) Income
    Income Tax
(Benefit) Expense
    Tax Rate     Net Income
(Loss)
    Diluted Earnings
(Loss) Per Share
 

As reported - GAAP

   $ (34.8   $ (1.9     5.5   $ (32.9   $ (0.19

Non-GAAP adjustments

     101.6       14.8         86.8    
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP

   $ 66.8     $ 12.8       19.2   $ 53.9     $ 0.30  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

Horizon Therapeutics plc      20  


LOGO

 

Horizon Therapeutics plc

Certain Income Statement Line Items - Non-GAAP Adjusted

For the Three Months Ended March 31, 2020

(Unaudited)

 

    COGS     Research &
Development
    Selling, General
& Administrative
    Interest
Expense
    Other
Expense
    Income Tax
Benefit
(Expense)
 

GAAP as reported

  $ (97,416   $ (27,209   $ (247,775   $ (17,344   $ 442     $ 19,026  

Non-GAAP Adjustments (in thousands):

           

Acquisition/divestiture-related costs(1)

    —         —         284       —         (290     —    

Amortization and step-up:

           

Intangible amortization expense(2)

    58,374       —         201       —         —         —    

Amortization of debt discount and deferred financing costs(3)

    —         —         —         5,569       —         —    

Share-based compensation(4)

    2,689       6,376       47,356       —         —         —    

Depreciation(5)

    328       25       6,812       —         —         —    

Fees related to refinancing activities (6)

    —         —         54       —         —         —    

Drug substance harmonization costs(7)

    290       —         —         —         —         —    

Income tax effect on pre-tax non-GAAP adjustments(8)

    —         —         —         —         —         (31,262
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total of non-GAAP adjustments

    61,681       6,401       54,707       5,569       (290     (31,262
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Non-GAAP

  $ (35,735   $ (20,808   $ (193,068   $ (11,775   $ 152     $ (12,236
 

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Horizon Therapeutics plc

Certain Income Statement Line Items - Non-GAAP Adjusted

For the Three Months Ended March 31, 2019

(Unaudited)

 

     COGS     Research &
Development
    Selling, General
& Administrative
    Loss on Debt
Extinguishment
    Interest
Expense
    Other
Income, net
     Income Tax
Benefit
(Expense)
 

GAAP as reported

   $ (88,142   $ (21,725   $ (172,299   $ (5,586   $ (27,530   $ 189      $ 1,920  

Non-GAAP Adjustments (in thousands):

               

Acquisition/divestiture-related costs(1)

     1,114       1       87       —         —         143        —    

Restructuring and realignment costs(9)

     —         —         20       —         —         —          —    

Amortization and step-up:

               

Intangible amortization expense(2)

     57,218       —         198       —         —         —          —    

Inventory step-up expense

     115       —         —         —         —         —          —    

Amortization of debt discount and deferred financing costs(3)

     —         —         —         —         5,912          —    

Share-based compensation(4)

     1,040       2,636       23,873       —         —         —          —    

Depreciation(5)

     159       —         1,314       —         —         —          —    

Upfront, progress and milestone payments related to license and collaboration agreements(10)

     —         2,000       —         —         —         —          —    

Loss on debt extinguishment(11)

     —         —         —         5,586       —         —          —    

Fees related to refinancing activities (6)

     —         —         142       —         —         —          —    

Drug substance harmonization costs(7)

     80       —         —         —         —         —          —    

Charges relating to discontinuation of Friedreich’s ataxia program(12)

     (79     —         —         —         —         —          —    

Income tax effect on pre-tax non-GAAP adjustments(8)

     —         —         —         —         —         —          (14,751
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

    

 

 

 

Total of non-GAAP adjustments

     59,647       4,637       25,634       5,586       5,912       143        (14,751
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

    

 

 

 

Non-GAAP

   $ (28,495   $ (17,088   $ (146,665   $ —       $ (21,618   $ 332      $ (12,831
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

    

 

 

 

 

Horizon Therapeutics plc      21  


LOGO

 

NOTES FOR CERTAIN INCOME STATEMENT LINE ITEMS - NON-GAAP

 

1.

Represents expenses, including legal and consulting fees, incurred in connection with our acquisitions and divestitures. Costs recovered from subleases of acquired facilities and reimbursed expenses incurred under transition arrangements for divestitures are also reflected in this line item.

 

2.

Intangible amortization expenses are associated with our intellectual property rights, developed technology and customer relationships related to KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, TEPEZZA, RAYOS, PENNSAID 2%, VIMOVO and MIGERGOT.

 

3.

Represents amortization of debt discount and deferred financing costs associated with our debt.

 

4.

Represents share-based compensation expense associated with our stock option, restricted stock unit and performance stock unit grants to our employees and non-employee directors, and our employee share purchase plan.

 

5.

Represents depreciation expense related to our property, equipment, software and leasehold improvements.

 

6.

Represents arrangement and other fees relating to our refinancing activities.

 

7.

During the year ended Dec., 2016, we entered into a definitive agreement to acquire certain rights to interferon gamma-1b, marketed as IMUKIN in an estimated thirty countries primarily in Europe and the Middle East, or the IMUKIN purchase agreement. We already owned the rights to interferon gamma-1b marketed as ACTIMMUNE in the United States, Canada and Japan. In connection with the IMUKIN purchase agreement, we also committed to pay our contract manufacturer certain amounts related to the harmonization of the manufacturing processes for ACTIMMUNE and IMUKIN drug substance, or the harmonization program. At the time we entered into the IMUKIN purchase agreement and the harmonization program commitment was made, we had anticipated achieving certain benefits should the Phase 3 clinical trial evaluating ACTIMMUNE for the treatment of Friedreich’s ataxia (FA), be successful. If the study had been successful and if U.S. marketing approval had subsequently been obtained, we had forecasted significant increases in demand for the medicine and the harmonization program would have resulted in significant benefits for us. Following our discontinuation of the FA program, we determined that certain assets, including an upfront payment related to the IMUKIN purchase agreement, were impaired, and the costs under the harmonization program would no longer have benefit to us and should be expensed as incurred.

 

8.

Income tax adjustments on pre-tax non-GAAP adjustments represent the estimated income tax impact of each pre-tax non-GAAP adjustment based on the statutory income tax rate of the applicable jurisdictions for each non-GAAP adjustment.

 

Horizon Therapeutics plc      22  


LOGO

 

9.

Represents expenses, including severance costs and consulting fees, related to restructuring and realignment activities.

 

10.

During the three months ended March 31, 2019, we recorded an upfront cash payment of $2.0 million in relation to the collaboration agreement with HemoShear.

 

11.

During the three months ended March 31, 2019, we recorded a loss on debt extinguishment of $5.6 million in the condensed consolidated statement of comprehensive loss, which reflects the write-off of the deferred financing and debt discount fees related to the $300.0 million term loan repayment.

 

12.

Represents expenses incurred relating to discontinuation of FA program and a reduction to previous charges recorded.

 

Horizon Therapeutics plc      23